http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Rugo, Hope S.,Tré,dan, Olivier,Ro, Jungsil,Morales, Serafin M.,Campone, Mario,Musolino, Antonino,Afonso, Noé,mia,Ferreira, Marta,Park, Kyong Hwa,Cortes, Javier,Tan, Antoinette R.,Blum, Joa Springer-Verlag 2017 Breast cancer research and treatment Vol.165 No.3
<P>R/D/E did not improve PFS compared with R/E. Because the PFS reported for R/E was similar to that reported for everolimus plus exemestane in patients with advanced breast cancer, it is possible that lower-dose ridaforolimus in the R/D/E arm (from overlapping toxicities with IGF1R inhibitor) contributed to lack of improved PFS.</P>
Vegetables, but not pickled vegetables, are negatively associated with the risk of breast cancer.
Yu, Hyejin,Hwang, Ji-Yun,Ro, Jungsil,Kim, Jeongseon,Chang, Namsoo Lawrence Erlbaum Associates, Publishers [etc.] 2010 Nutrition and cancer Vol.62 No.4
<P>This study investigated the association between pickled vegetable consumption and the risk of breast cancer using a validated food frequency questionnaire. A total of 358 patients with breast cancer who were matched to 360 healthy controls by age (using a 5-yr age distribution) were recruited from the National Cancer Center in South Korea. After adjusting for nondietary risk factors, total vegetable intake was inversely associated with risk of breast cancer. However, unlike nonpickled vegetables, pickled vegetable intake and its proportion relative to total vegetables were positively associated with the risk of breast cancer, and this association was more profound and consistent when pickled vegetable intake was considered as a proportion relative to total vegetables (odds ratio [OR] = 6.24, 95% confidence interval [CI] = 3.55-10.97; P for trend <0.001 for highest vs. lowest quartiles of intake) than as the absolute consumed amount (OR = 2.47, 95% CI = 1.45-4.21; P for trend = 0.015 for highest vs. lowest quartiles of intake). These results suggest that not only the amount of total vegetable intake but also the amounts of different types of vegetable (i.e., pickled or nonpickled) and their proportions relative to total vegetables are significantly associated with the risk of breast cancer.</P>
Kim, Ji-Yeon,Im, Seock-Ah,Jung, Kyung Hae,Ro, Jungsil,Sohn, Joohyuk,Kim, Jee Hyun,Park, Yeon Hee,Kim, Tae-Yong,Kim, Sung-Bae,Lee, Keun Seok,Kim, Gun Min,Kim, Se Hyun,Kim, Seonwoo,Ahn, Jin Seok,Lee, Ky Elsevier 2018 European journal of cancer Vol.103 No.-
<P><B>Abstract</B></P> <P><B>Background</B></P> <P>We investigated the efficacy and safety of fulvestrant plus goserelin (F + G) versus anastrozole plus goserelin (A + G) in comparison with goserelin (G) alone in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), tamoxifen-pretreated metastatic breast cancer (MBC).</P> <P><B>Patients and methods</B></P> <P>In this multicentre, open-label, randomised phase II study, premenopausal women aged ≥18 years with HR+, HER2–, tamoxifen-pretreated MBC were randomly assigned (1:1:1) to F + G, A + G or G alone. The primary end-point was time to progression (TTP). Secondary end-points included overall survival, overall response rate, clinical benefit rate and toxicity.</P> <P><B>Results</B></P> <P>Of 138 eligible patients, 44 were randomly assigned to receive F + G, 47 to A + G and 47 to G alone. The median follow-up duration was 32.2 months (interquartile range: 23.69–40.86) and the median age was 43.0 years (range 23.0–55.0). The median TTP was 16.3 months (95% confidence interval [CI] 7.5–25.1) for F + G, 14.5 months (95% CI 11.0–18.0) for A + G and 13.5 months (95% CI 10.3–16.8) for G alone. Compared with G alone, the hazard ratios were 0.608 for F + G (95% CI, 0.370–0.998; p = 0.049) and 0.982 for A + G (95% CI, 0.624–1.546; p = 0.937). In terms of visceral metastasis, a stratification factor, there were no TTP differences according to treatment arm. Grade III or IV toxicities were rarely observed. Of the common adverse events, grade I arthralgia and joint stiffness were more frequently observed in the F + G than in the A + G or G-alone groups (p < 0.05, respectively).</P> <P><B>Conclusions</B></P> <P>F + G provides a promising new option for the treatment of premenopausal women with HR+, HER2-, tamoxifen-pretreated MBC.</P> <P><B>Trial registration</B></P> <P>ClinicalTrials.gov number NCT01266213 and Korean Cancer Study Group (KCSG) Breast cancer protocol number BR10-04.</P> <P><B>Highlights</B></P> <P> <UL> <LI> In premenopausal women with hormone receptor-positive metastatic breast cancer, hormone treatment similar to that used in postmenopausal women is the standard treatment option after tamoxifen treatment failure. </LI> <LI> In this study, fulvestrant plus goserelin (G) has better clinical outcome than G alone in premenopausal women, especially those younger than 40 years. </LI> <LI> Aromatase inhibitor with G is not superior to G alone in tamoxifen-pretreated premenopausal women. </LI> </UL> </P>
Park, In Hae,Kang, Joo Hyun,Lee, Keun Seok,Nam, Seungyoon,Ro, Jungsil,Kim, Joo-Hang Saikon Pub. Co 2014 TUMOR BIOLOGY Vol.35 No.12
<P>Cancer-associated microRNAs have been stably detected in blood. The objective of this study was to identify a panel of circulating microRNAs with the potential to serve as biomarkers for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2 (HER2)- breast cancer. We used microarray-based expression profiling to compare the levels of circulating microRNAs in blood samples from 11 ER+/HER2- advanced breast cancer patients plus 5 age-matched controls. MicroRNA levels were validated by reverse transcription quantitative polymerase chain reaction in 40 control subjects, 187 early breast cancer patients, and 45 metastatic breast cancer patients. Then, we assessed the association between the levels of microRNA and clinical outcomes of ER+/HER2- metastatic breast cancer. Initially, we found that miR-1280, miR-1260, and miR-720 were up-regulated in blood from breast cancer patients (P?<?0.05). In validation, miR-1280 levels significantly increased in breast cancer patients and reflected tumor status (control<early cancer<metastatic cancer). Among 37 metastatic breast cancer patients, miR-1280 levels significantly decreased after treatment in patients who responded to systemic treatment (P?<?0.001). We confirmed that miR-1280 was not a classic microRNA, but a tRNA(Leu)-derived fragment. These findings suggest that a circulating tRNA-derived microRNA, miR-1280, is differently expressed in breast cancer patients and may serve as a biomarker for ER-positive breast cancer.</P>
Park, Yeon Hee,Jung, Kyung Hae,Im, Seock-Ah,Sohn, Joo Hyuk,Ro, Jungsil,Ahn, Jin-Hee,Kim, Sung-Bae,Nam, Byung-Ho,Oh, Do Youn,Han, Sae-Won,Lee, Soohyeon,Park, In Hae,Lee, Keun Seok,Kim, Jee Hyun,Kang, S M. Nijhoff ; Kluwer Academic Publishers 2015 Breast cancer research and treatment Vol.152 No.1
<P>The therapeutic goals are palliative for metastatic breast cancer (MBC) and include prolongation of survival with good quality of life (QoL) and symptom control. The purpose of this study was to examine QoL among women with MBC treated on KCSG-BR07-02 with maintenance of paclitaxel plus gemcitabine (PG) chemotherapy after achieving disease control to initial six cycles of PG chemotherapy or observation. Patients were randomized to either maintenance chemotherapy or observation until progression. QoL was assessed using EORTC QLQ-C30 and BR-23. QoL at each cycle was compared between the two treatment arms using the 2-sample t test. Generalized estimating equation method was used to examine the overall difference between the two treatments in QoL. All reported p-values are 2 sided. There were no statistically significant differences between two arms in most of the component of the EORTC QLQ-C30 and BR-23 (p > 0.05). There was no significant difference between two treatments (p = 0.6094 for QLQ-C30, p = 0.5516 for BR23) at baseline, and there did not exist significant change over the cycle (p = 0.0914 for QLQ-C30, p = 0.7981 for BR23). There was no significant interaction effect between treatment and cycle (p = 0.5543 for QLQ-C30. p = 0.5817 for BR23). Maintenance PG chemotherapy in patients with MBC achieving disease control with an initial six cycles of PG chemotherapy resulted in better PFS and OS compared to observation without impeding QoL.</P>
Park, Yeon Hee,Jung, Kyung Hae,Im, Seock-Ah,Sohn, Joo Hyuk,Ro, Jungsil,Ahn, Jin-Hee,Kim, Sung-Bae,Nam, Byung-Ho,Oh, Do Youn,Han, Sae-Won,Lee, Soohyeon,Park, In Hae,Lee, Keun Seok,Kim, Jee Hyun,Kang, S American Society for Clinical Oncology 2013 Journal of clinical oncology Vol.31 No.14
<P><B>Purpose</B></P><P>The primary purpose of our study was to evaluate whether maintenance chemotherapy with paclitaxel/gemcitabine (PG) was superior to observation in improving progression-free survival (PFS) in patients with metastatic breast cancer (MBC) who achieved disease control with an initial six cycles of PG as their first-line treatment.</P><P><B>Patients and Methods</B></P><P>The study was a prospective, randomized, multicenter, phase III trial. Patients MBC with who achieved disease control after six cycles of PG chemotherapy were randomly assigned to maintenance chemotherapy or observation until progression.</P><P><B>Results</B></P><P>Of 324 patients from 10 centers enrolled, 231 patients with MBC exhibited disease control (complete response + partial response + stable disease) with first-line PG and were randomly assigned to maintenance chemotherapy (n = 116) or observation (n = 115). The median age was 48 years (range, 28 to 76 years), median follow-up was 33 months, and median number of chemotherapy cycles in the maintenance group after random assignment was six. The median PFS time after random assignment was longer in the maintenance group than in the observation group (7.5 <I>v</I> 3.8 months, respectively; <I>P</I> = .026). The median overall survival (OS) time was longer in the maintenance group than in the observation group (32.3 <I>v</I> 23.5 months, respectively; <I>P</I> = .047). The rate of grade 3 or higher neutropenia after random assignment was higher in the maintenance group than in the observation group (61% <I>v</I> 0.9%, respectively; <I>P</I> < .001).</P><P><B>Conclusion</B></P><P>In patients with MBC who achieved disease control with an initial six cycles of PG chemotherapy, maintenance PG chemotherapy resulted in better PFS and OS compared with observation.</P>